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RESEARCH DESIGN AND METHODS
Subjects. Nine patients with type 1 diabetes and negative Cpeptide response to an arginine test and eight healthy subjects with normal glucose tolerance (assessed by 75-g OGTT) and without family history of diabetes were studied (characteristics in Table 1 ). The patients had no diabetic complications or other medical illnesses. They were treated with long-acting insulin (Insulatard, Novo Mix, Lantus, or Levemir) and rapid-acting insulin (Actrapid or Novorapid). Before inclusion, the patients were challenged with an arginine test (5 g arginine given as an iv bolus) to ensure that they were without residual insulin secretion (plasma C-peptide Ͻ0.1 ng/ml before and 5, 10, and 15 min after the arginine bolus injection).
Methods. The two experimental days were separated by at least 48 h and consisted of 50-g OGTT and IIGI, respectively, following a 10-h fast, as previously described (11, 12) . All subjects were instructed to maintain habitual lifestyle and to abstain from alcohol and strenuous exercise 48 h before examinations. Patients with type 1 diabetes took their long-acting insulin the night before each experimental day but were instructed not to take any insulin from that point on until completion of the experimental day in question. If symptomatic hypoglycemia or blood glucose measurements below 3 mM had occurred within 48 h of planned investigations, the examination was postponed to make sure that compensatory hyperglucagonemia had passed. Subjects were asked to empty their bladder before and after each experiment to measure the amount of glucose excreted by the kidneys during the two glucose administration forms. Analyses. PG and urine glucose concentrations were measured using a glucose oxidase method (Glucose Analyzer, Yellow Springs Instrument Model: YSI 2300 STAT plus analyzer). Plasma C-peptide concentrations were measured using ElectroChemiLuminescens ImmunoAssay (Roche/Hitachi Modular Analytics; Roche Diagnostic, Mannheim, Germany) (1). Plasma concentrations of glucagon, total glucagon-like peptide-1 (GLP-1), intact glucagon-like peptide-2 (GLP-2), and total glucose-dependent insulinotropic polypeptide (GIP) were measured by RIAs as previously described (5, 6, 13, 24) .
Statistical analyses and calculations. All results are presented as means Ϯ SE unless otherwise stated. Normally distributed data within the groups were compared using paired, two-tailed t-tests, and comparisons between the two groups were made using unpaired tests. Two-way repeated-measures (rm)ANOVA and post hoc tests (Bonferroni) were used as appropriate. P values Ͻ0.05 were considered statistically significant. Area under curve (AUC) values were calculated using the trapezoidal rule. The incretin effect was calculated by relating the difference in ␤-cell secretory responses between stimulation with OGTT and IIGI to the response after OGTT, which was taken as 100% {incretin effect (%) ϭ 100% [(AUCOGTT Ϫ AUCIIGI)/ AUC OGTT]} (19) . Gastrointestinal-mediated glucose disposal (GIGD) was calculated using our newly developed formula for OGTT and isoglycemic intravenous clamp experiments, which describes the impact of gastrointestinal factors on glucose disposal following OGTT compared with IIGI: GIGD (%) ϭ 100% ϫ (glucoseOGTT Ϫ glucoseIIGI)/glucoseOGTT. The formula relates the difference between the 50 g of glucose ingested (through the gastrointestinal tract) and the amount of glucose needed to be infused intravenously to mimic the PGOGTT curve, to the 50 g of glucose ingested orally. The result of the formula answers the question "What percentage of an individual's glucose disposal is caused by the oral route of glucose administration?". Thus, the formula describes not only the impact of the incretin effect (insulinotropic substances released upon intestinal stimulation) but includes all factors affecting PG concentrations differently during the two administration forms (including neural reflexes, activation of afferent nerves in the intestinal mucosa, differences in glucagon secretion, first-pass hepatic uptake of glucose, differences in portal Data are means Ϯ SD. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c. *Significant difference (P Ͻ 0.001) from healthy control subjects. and venous blood glucose concentrations, and/or at the present unknown factors).
RESULTS

Glucose.
The fasting PG concentrations on the two experimental days were similar for both groups but significantly higher in the patients compared with healthy controls. The PG curves are shown in Fig. 1 . Isoglycemia during the OGTT and IIGI experiments was obtained by intravenous infusion of 53 Ϯ 5 g glucose in the patients and 30 Ϯ 3 g in the healthy control subjects (P Ͻ 0.001) during IIGIs, leading to GIGD values of Ϫ6 Ϯ 9 and 40 Ϯ 6% in the two groups, respectively (P Ͻ 0.01). As indicated in Table 2 , AUC PG values were threefold greater in patients compared with controls. Control subjects had no urinary excretion of glucose, whereas the patients with type 1 diabetes excreted equal amounts of glucose during the OGTT and IIGI (24 Ϯ 5 vs. 28 Ϯ 6 g, P ϭ 0.44).
C-peptide. Patients with type 1 diabetes had undetectable plasma C-peptide concentrations in the fasting state and during OGTT and IIGI. In contrast, healthy control subjects exhibited a characteristically large OGTT response and a smaller response to the IIGI ( Fig. 1 and Table 2 ), reflecting an intact incretin effect of 45 Ϯ 4% (19, 21) .
Glucagon. There were no differences in fasting plasma glucagon on the two experimental days in any of the groups and no differences in mean fasting values between the groups (Table 2) . Healthy subjects were able to suppress plasma glucagon equally during OGTT and IIGI [two-way rmANOVA: P ϭ not significant (NS); Fig. 1 and Table 2 ] to mean nadir values of 3.4 Ϯ 0.4 and 3.4 Ϯ 0.5 pM (P ϭ 1.00) at mean nadir times of 63 Ϯ 8 and 49 Ϯ 4 min (P ϭ 0.11), respectively. In contrast, patients with type 1 diabetes exhibited different glucagon responses during the two glucose stimuli (two-way rmANOVA: P Ͻ 0.0001, with post hoc analysis showing significant differences at time points 20, 30, 40 , and 60 min), displaying initial net secretion (mean maximum concentration of 10.1 Ϯ 1.2 pM) and delayed suppression (mean nadir time at 129 Ϯ 29 min and mean nadir concentration of 4.4 Ϯ 0.5 pM) following the OGTT, whereas the IIGI resulted in glucagon suppression equal to the suppression observed among healthy control subjects during OGTT and IIGI ( Fig. 1 and Table 2 ) with a mean nadir concentration of 3.6 Ϯ 0.4 pM (P ϭ 0.6 vs. healthy subjects and P ϭ 0.068 vs. OGTT) at a mean nadir time of 84 Ϯ 21 min (P ϭ 0.14 vs. healthy subjects and P ϭ 0.079 vs. OGTT). However, comparing the OGTT responses in the two groups with two-way rmANOVA, no statistical significance was observed. Nevertheless, during the initial 40 min of the OGTT, patients with type 1 diabetes exhibited an impaired glucagon response (with paradoxical hypersecretion) compared with control subjects (37 Ϯ 13 vs. Ϫ65 Ϯ 28 pM·min, P Ͻ 0.01); in this period, an even more pronounced difference between the two glucose stimuli (37 Ϯ 13 vs. Ϫ22 Ϯ 16 pM·min, P Ͻ 0.01) was observed among the patients with type 1 diabetes. No such difference was observed among healthy control subjects (Ϫ65 Ϯ 28 vs. Ϫ86 Ϯ 13 pM·min, P ϭ NS).
GLPs. No differences in plasma GLP-1 or GLP-2 responses to oral glucose were observed between patients with type 1 diabetes and healthy subjects. However, judging from the curves in Fig. 2 , it is clear that patients with type 1 diabetes exhibited a more brisk increase in plasma GLP-1 compared with controls, resulting in significantly higher mean plasma values at time point 30 min (18 Ϯ 2 vs. 12 Ϯ 1 pM, P Ͻ 0.01). The same was true for GLP-2 at time 40 min (38 Ϯ 5 vs. 24 Ϯ 3 pM, P Ͻ 0.05). Significant (P Ͻ 0.01) positive correlations between GLP-1 and GLP-2 responses to OGTT were observed (data not shown). No significant GLP-1 or GLP-2 responses occurred during IIGI in any of the two groups (Fig. 2) .
GIP. No differences in fasting GIP values or plasma GIP responses to OGTT (or IIGI where no significant responses occurred in any of the groups) were observed between the two groups ( Fig. 2 and Table 2 ).
DISCUSSION
Here we report the first study applying OGTT and IIGI in C-peptide-negative patients with type 1 diabetes (and healthy control subjects). Our novel findings include 1) significant difference between glucagon responses to OGTT and IIGI in patients with type 1 diabetes, and 2) normal OGTT responses of the gut hormones GIP, GLP-1 and GLP-2 in patients with type 1 diabetes and no residual ␤-cell function.
Lack of suppressive effect of hyperglycemia and reduced or lack of intraislet insulin have been suggested to play important roles in the inappropriately elevated plasma glucagon levels of diabetic patients (2, 3, 8, 25, 26, 28, 31) . However, our group has recently provided data suggesting that gut-derived factors may be involved (11, 12) . Likewise, Meier et al. (15) have shown that the phenomenon of paradoxical glucagon responses to oral as opposed to intravenous glucose, in a somewhat "lighter" version, also seems to occur in healthy subjects when they are examined with larger oral glucose loads (75-g OGTT) and IIGIs, a finding that we recently confirmed and found to be even more pronounced when 125-g OGTTs and corresponding IIGIs are applied in healthy subjects (10) .
To get a clearer picture of the potential involvement of gut-derived factors in the differential glucagon response to oral and intravenous glucose, we applied the isoglycemic clamp method to C-peptide-negative patients with type 1 diabetes. Because these patients were investigated under isoglycemic conditions during the two experimental days, intraislet insulin and differences in glucose concentrations per se cannot be important determinants of the differential glucagon responses we observed (inappropriate glucagon response to OGTT vs. ability to suppress glucagon during IIGI).
A possible explanation for the different glucagon responses during OGTT and IIGI could be sought in the secretion of gut hormones known to affect ␣-cell secretion. GLP-1 has been shown to inhibit glucagon secretion (14, 22) , whereas GIP has been shown to enhance glucagon secretion (16, 20) very much like GLP-2 (17, 27, 29) . However, because no apparent differences between the groups with regard to GIP, GLP-1, or GLP-2 responses were observed, different secretion patterns between the groups do not seem to be a cause. Rather, it would appear that a reduced inhibitory effect of glucose or insulin secretion in the patients with type 1 diabetes might allow an initial gut stimulation effect on glucagon secretion (e.g., by GIP or GLP-2) to be seen. Theoretically, decreased ␣-cell sensitivity to GLP-1 could also play a role. However, in a recent study in patients with type 2 diabetes, GLP-1-induced suppression was normal (4) . Whether ␣-cell sensitivity to GIP or GLP-2 is altered in patients with diabetes remains to be established.
Another hypothetical explanation of the discrepancy between glucagon responses during gastrointestinal-delivered glucose (OGTT) and intravenous delivered glucose (IIGI) could be sought in the small intestinal endocrine L cells, which under normal conditions secrete GLP-1 (and GLP-2) in response to nutrient ingestion (7) . Both L cells and pancreatic ␣-cells express the proglucagon gene (7) . In L cells, proglucagon is processed to GLP-1 and GLP-2 by prohormone convertase 1 (PC1), whereas ␣-cells utilize prohormone convertase 2 to process proglucagon to glucagons (7) . Interestingly, in PC1-deficient mice, the processing of proglucagon to GLP-1 and GLP-2 is significantly reduced (30, 32) , whereas plasma glucagon levels are increased (30) . Furthermore, a case of human PC1 deficiency revealed elevated postprandial plasma levels of glucagon and proglucagon (9) . It can therefore be speculated that proglucagon moieties in the L cells of diabetic patients are processed partially to glucagon, explaining the increased glucagon response following OGTT compared with IIGI. Ongoing studies on jejunal biopsies from diabetic patients and healthy control subjects will hopefully provide a clearer picture regarding this hypothesis.
An apparent weakness of the present study is the lack of data on gastric emptying rates. One can speculate that the different glucagon responses to OGTT observed among patients with type 1 diabetes and healthy control subjects can be ascribed to different gastric emptying rates between the two groups. However, none of the patients in the present study had gastroparesis or a history of upper abdominal symptoms. Furthermore, equal slopes of the rises in PG together with identical increases in gastrointestinal hormones indicate that the two groups absorbed the oral glucose load equally. Therefore, we believe, it is unlikely that our patients suffered from reduced gastric emptying that would affect glucagon responses. One of the primary aims of the present study was to compare glucagon responses to glucose delivered through the gastrointestinal tract with glucagon responses elicited by glucose infused intravenously (mimicking the PG OGTT curve Ϫ isoglycemic conditions) in the same patient without residual ␤-cell function, and, to assess the normality of the type 1 diabetic glucagon responses, healthy control subjects were also investigated using 50-g OGTT and IIGI. Even though this design excludes differential effects of peripheral PG concentrations within the same group, differences between the two groups cannot be excluded because of different glycemic levels. Last, we cannot exclude an effect of exogenous insulin in our patients, since these were treated with long-acting insulin or insulin analogs. However, a possible effect of exogenous insulin is most likely identical during the two experimental days and does not change the fact that our patients lack intraislet insulin inhibition on the ␣-cells during both oral and intravenous glucose.
The isoglycemic clamp technique has traditionally been used to evaluate the incretin effect in humans. The incretin effect is defined as the potentiating effect of GIP and GLP-1 (the incretin hormones) on insulin secretion. The healthy subjects participating in the present study exhibited a substantially increased insulin secretion (assessed by plasma C-peptide responses) after OGTT compared with IIGI, resulting in a normal-sized incretin effect of 45% (19, 21) . Patients with type 1 diabetes (and no residual ␤-cell function) will per definition have no incretin effect, reflected in the absence of plasma C-peptide responses to either stimuli in our patients. However, their preserved ability to suppress glucagon during IIGI, as opposed to their hypersecretion and delayed suppression of glucagon during OGTT, must be assumed to affect the glucose tolerance under the two conditions differentially (via amplified glucagon-stimulated hepatic glucose production during the OGTT). To take this into account, we employed the formula for GIGD, which came out with a negative mean value (however nonsignificantly different from zero, possibly reflecting a statistical type 2 error) among patients with type 1 diabetes, indicating that the paradoxical hyperglucagonemia occurring during OGTT (but not during IIGI) perhaps is associated with a negative impact on the glucose disposal in type 1 diabetic patients.
In conclusion, our data suggest that gastrointestinal factors contribute to the impaired glucagon response to OGTT in patients with type 1 diabetes.
